Source: Health Products Regulatory Authority (IE) Revision Year: 2021 Publisher: Menarini International Operations Luxembourg S.A., 1 Avenue de la Gare, 1611 Luxembourg
ZOFENIL 7.5 mg film-coated tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet. White round film-coated tablets with convex faces. |
Each ZOFENIL 7.5 mg tablet contains 7.5 mg of zofenopril calcium as 7.2 mg of zofenopril.
Excipients with known effect: Each ZOFENIL 7.5 mg film-coated tablet contains 17.35 mg of lactose monohydrate.
For a full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Zofenopril |
The beneficial effects of zofenopril in hypertension and acute myocardial infarction appear to result primarily from the suppression of the plasma renin-angiotensin aldosterone system. Inhibition of ACE (Ki 0.4nM in rabbit lung for arginine salt of zofenoprilat) results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and to reduced aldosterone secretion. |
| List of Excipients |
|---|
|
Core: Microcrystalline cellulose Coat: Hypromellose |
Blister PVDC /PVC/aluminium or Aclar/Aluminium or PVC/PE/PVDC/Aluminium, packs of: 12, 14, 15, 28, 30, 48, 50, 50 unit doses, 56, 56 unit doses, 90 or 100 film coated tablets.
Not all pack sizes may be marketed.
Menarini International Operations Luxembourg S.A., 1 Avenue de la Gare, 1611 Luxembourg
PA0865/003/001
Date of first authorisation: 04 March 1999
Date of last renewal: 30 July 2008
| Drug | Countries | |
|---|---|---|
| ZOFENIL | Austria, Germany, France, Ireland, Poland |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
